[1] |
Chen W, Zheng R, Baade PD,et al.Cancer statistics in China,2015 [J].CA Cancer J Clin,2016,66(2):115-132.
|
[2] |
李依敏,苏思贞,朱静,等.乳腺癌靶向治疗药物治疗研究进展 [J].山东医药,2017,57(9):107-109.
|
[3] |
中国抗癌协会乳腺癌专业委员会.Her-2阳性乳腺癌临床诊疗专家共识 [J].中国癌症杂志,2012,22(4):314-318.
|
[4] |
江泽飞,邵志敏,徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016 [J].中华医学杂志,2016,96(14):1091-1096.
|
[5] |
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 [J]. Ann Oncol, 2017, 28(8): 1700-1712.
|
[6] |
U.S.Food and Drug Administration.FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer[EB/OL].[2019-07-01].
URL
|
[7] |
Gianni L, Pienkowski T, Im YH,et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER-2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J]. Lancet Oncol, 2016, 17(6): 791-800.
|
[8] |
von Minckwitz G, Procter M, de Azambuja E,et al.Adjuvant pertuzumab and trastuzumab in eraly HER-2-positive breast cancer [J].N Engl J Med,2017,377(2):122-131.
|
[9] |
Swain SM, Baselga J, Kim SB,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer [J].N Engl J Med, 2015, 372(8): 724-734.
|
[10] |
Loi S,,Giobbe-Hurder A,,Gombos A,et al. PhaseⅠb/Ⅱstudy evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER-2-positive metastatic breast cancer:Results from the PANACEA (IBCSG45-13/KEYNOTE-014) study[EB/OL].[2019-06-01].
URL
|
[11] |
Rugo HS, Im SA, Cardoso F,et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2 positive advanced breast cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol,2021,7(4):573584.
|
[12] |
vonMinckwitz G, Huang CS, Mano MS,et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J].N Engl J Med,2019,380(7):617-628.
|
[13] |
Sakai H, Tsurutani J, Iwasa T, et al.HER-2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER-2-positive metastatic breast cancer [J].Breast Cancer,2018,25(5): 605-613.
|
[14] |
Hongbin W, Wenqin W, Yanping X,et al.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells [J].Cancer Sci,2017,108(7):1458-1468.
|
[15] |
U.S.Food and Drug Administration.FDA approves new treatment to reduce the risk of breast cancer returning [EB/OL].[2019-07-01].
URL
|
[16] |
Chan A, Delaloge S, Holmes FA,te al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER-2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled,phase 3 trial [J]. Lancet Oncol, 2016, 17(3): 367-377.
|
[17] |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER-2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebocontrolled, phase 3 trial [J]. Lancet Oncol, 2017, 18(12): 1688-1700.
|
[18] |
Fei Ma, Quchang Ouyang, Wei Li,et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase Ⅱ study [J].J Clin Oncol,2019,37(29):2610-2619.
|
[19] |
Xu B, Yan M, Ma F,et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial [J]. Lancet Oncol,2021,22(3):351-360.
|
[20] |
Zhou Z, Qiao JX, Shetty A,et al. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy [J].Cell Mol Life Sci,2014,71(8):1549.
|
[21] |
金科,赵丹,杨林,等.CDK4/6抑制剂联合内分泌治疗对乳腺癌细胞miRNA表达水平的影响 [J]. 现代肿瘤医学,2019,27(5):723-727.
|
[22] |
国家药品监督管理局.2018年审评通过的优先审评药品名单[EB/OL].[2019-07-01].
URL
|
[23] |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first line therapy for HR-positive, advanced breast cancer [J]. N Engl J Med, 2016, 375(18):1738-1748.
|
[24] |
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J]. Lancet Oncol, 2018, 19(7):904-915.
|
[25] |
Slamon DJ, Neven P, Chia S,et al.Phase Ⅲ randomized study of ribociclib and Fulvestrant in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3 [J].J Clin Oncol,2018,36(24):2465-2472.
|
[26] |
Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer [J]. N Engl J Med,2019,381(4):307-316.
|
[27] |
O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial[J]. Cancer Discov, 2018,8(11):1390-1403.
|
[28] |
Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer [J].N Engl J Med,2015,373(3):209-219.
|
[29] |
Hares SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer [J].Am J Cancer Res,2017,7(3):383-404.
|
[30] |
Paplomata E, O’Regan R.The PI3K/AKT/mTOR pathway in breast cancer:targets,trials and biomarkers [J].Ther Adv Med Oncol,2014,6(4):154-166.
|
[31] |
Tesch H, Stoetzer O, Decker T,et al.Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase ⅢB 4EVER trial [J].Int J Cancer,2019,144(4):877-885.
|
[32] |
Jones RH, Casbard A, Carucci M,et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial[J]. Lancet Oncol,2020,21(3):345-357.
|
[33] |
Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry[J]. Cancer,2007,109(9):1721-1728.
|
[34] |
国家药品监督管理局.首个国产PD-1抗体药物特瑞普利单抗注射液获批上市 [EB/OL].[2018-12-17].
URL
|
[35] |
黄述斌,侯永微,李松梅,等.乳腺癌组织及间质浸润淋巴细胞中PD-L1的表达及其意义 [J].临床与实验病理学杂志,2017,33(1):63-67.
|
[36] |
Cimino-Mathews A, Thompson E, Taube J M,et a1.PD-L1(B7-H1 ) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas [J].Human Pathol,2016,47(1):52-63.
|
[37] |
Nanda R, Specht J, Dees C,et al.KEYNOTE-012:long-lasting response in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC) [J]. Cancer Res,2017, 77(4 Suppl):P6-10-03.
|
[38] |
Adams S, Loi S, Toppmeyer D, et at. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC):preliminary data from KEYNOTE-086 cohort B [J].J Clin Oncol,2017,35(15 Suppl):1088.
|
[39] |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med,2018,379(22):2108-2121.
|
[40] |
Schmid P, Rhgo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion 130): updated efficacy, from a randomised,double-blind placebo-controlled,phase 3 trial [J]. Lancet Oncol, 2020, 21(1): 44-59.
|
[41] |
Schmid P, Adams S, Rugo HS,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J].N Eng J Med,2018,379(22):2108-2121.
|
[42] |
U.S. Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer[EB/OL].[2019-03-08].
URL
|
[43] |
Sikov WM, Berry DA, Perou CM,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J]. J Clin Oncol,2015,33(1):13-21.
|
[44] |
Symonds L, Linden H, Gadi V,et al.Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer-a phase Ⅱ trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib [J].Clin Breast Cancer,2019,19(2):e283-e296.
|
[45] |
Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer Sci,2011,102(7):1374-1380.
|
[46] |
鲁凯莉.阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效探讨 [J].中国处方药,2018,16(6):75-76.
|
[47] |
Li YH, Zhou Y, Wang YW,et al.Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study [J].Medicine (Baltimore),2018,97 (36):e12222.
|
[48] |
Lee LJ, Alexander B, Schnitt SJ,et al.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers [J].Cancer,2011,117( 14): 3093-3100.
|
[49] |
Hu T, Liu C, Li Q,et al. Tapatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer:Case report and literature review [J].Medicine (Baltimore), 2018, 97(15):e0349.
|
[50] |
Li T, Wang SB, Lei KJ,et al. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer:A case report [J].Medicine (Baltimore),2019,98(4):e14182.
|
[51] |
张秀伟,钟文,魏士博,等.三阴性乳腺癌与PARP1表达相关性的Meta分析 [J].现代肿瘤医学,2017,25(6):893-896.
|
[52] |
Vinayak S, Tolaney SM, Schwartzberg L,et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer[J]. JAMA Oncol,2019,5(8):1132-1140.
|
[53] |
Pietri E, Conteduca V, Andreis D, et al. Androgen receptor signaling pathways as a target for breast cancer treatment [J]. Endocr Relat Cancer,2016,23(10):R485-498.
|
[54] |
Lyons T, Gucalp A, Arumov A, et al. Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer[J]. J Clin Oncol,2018,36(15 suppl):531.
|
[55] |
Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer [J]. J Clin Oncol, 2018,36(9):884-890.
|
[56] |
Schmid P, Abraham J, Chan S, et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase Ⅱ trial[J]. J Clin Oncol,2018,36(15 suppl):1007.
|